<DOC>
	<DOCNO>NCT01967810</DOCNO>
	<brief_summary>This Phase 2 study see investigational drug , ANG1005 , shrink tumor cell patient high-grade glioma . Another purpose study ass efficacy , safety , tolerability , pharmacokinetics ( PK ) ANG1005 patient .</brief_summary>
	<brief_title>ANG1005 Patients With Recurrent High-Grade Glioma</brief_title>
	<detailed_description>See .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . ≥ 18 year old 2 . GBM GBM variant , WHO Grade III anaplastic glioma diagnosis confirm 3 . Radiologically confirm recurrent bidimensionally measurable disease per Response Assessment NeuroOncology ( RANO ) criteria 4 . Neurologically stable 5 . For bevacizumabrefractory patient , radiologic demonstration tumor progression bevacizumab therapy 6 . Karnofsky performance status ( KPS ) ≥ 70 1 . More three relapse 2 . Previous ANG1005/GRN1005 treatment 3 . Radiotherapy within 3 month . 4 . Therapy bevacizumab within 4 week prior screen recurrent WHO grade III anaplastic glioma patient ( Arm 3 ) 5 . Evidence significant intracranial hemorrhage 6 . Previous taxane treatment 7 . Prior therapy bevacizumab bevacizumabnaïve patient ( Arm 1 ) 8 . NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) v4.0 Grade ≥ 2 neuropathy 9 . Inadequate bone marrow reserve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>glioma</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>brain cancer</keyword>
	<keyword>brain tumor</keyword>
	<keyword>recurrent</keyword>
</DOC>